ValiRx plc (AIM:VAL)

Market Cap	2.06M
Revenue (ttm)	9.60K
Net Income (ttm)	-1.97M
Shares Out	374.35M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	647,942
Average Volume	1,191,758
Open	0.5150
Previous Close	0.5500
Day's Range	0.5110 - 0.6000
52-Week Range	0.3750 - 4.4900
Beta	-0.60
RSI	44.93
Earnings Date	Apr 25, 2025

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 16
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL